Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioSeek, a subsidiary of Asterand, has signed a two-year collaboration agreement with Eisai, a research-based human health care company headquartered in Japan.
Subscribe to our email newsletter
As per the agreement, BioSeek is expected to apply its proprietary BioMAP platform to advance Eisai’s multiple discovery projects in the oncology and inflammation areas. The agreement encompasses scientific projects at Eisai sites in the US and Japan. The financial terms include research funding, success milestones payments and license fees.
BioSeek said that BioMAP Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in human pharmacology and toxicology. Depending on their mechanism of action, drug compounds induce specific patterns of changes in these systems (BioMAP profiles) that can be compared to a large number of reference profiles in the BioMAP Database.
Additionally, BioMAP provides early insight into human pharmacological and toxicological properties of compounds, including on- and off-target effects, dose responses, and the discrimination of closely related compounds.
Martyn Coombs, CEO of Asterand, said: “We are honoured that Eisai has chosen to incorporate BioSeek’s BioMAP technology platform into its drug discovery process. We look forward to assisting Eisai in its quest to develop new therapies for cancer and inflammatory conditions.”
Asterand provides human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery.